The unveiling of a new diagnostic radiopharmaceutical for prostate cancer by the Atomic Energy Organization

according to the foreign policy group Tasnim news agency, in The second exhibition of knowledge-based products in the field of food, medicine and medical equipment from the new radiopharmaceutical of the Atomic Energy Organization under the brand name of Pars Tecto (PARS-TECTO-PSMA) made in Pars Isotope Company with the presence of Mohammad Eslami, Vice President and Head of the Atomic Energy Organization, Bahram Ain Allahi, Minister of Health, Treatment and Medical Education, Ruhollah Dehghani Firouzabadi, Vice President for Science, Technology and Knowledge-Based Economy, was unveiled. The country, synthesized and formulated and used, makes it possible to diagnose “prostate” cancer in the early stages with the new imaging method in the SPECT method faster and compared to the previous methods of imaging with PET cameras and the limitations of the centers that have these devices. It can be done at a lower cost. In this method, after marking this kit with technetium m99 radioisotope, imaging will be possible in all nuclear medicine centers. “Prostate” is connected in the body and by providing appropriate and more accurate information about the size and location of the tumor to the attending physician, it provides a better possibility to follow up and observe the patient’s recovery process.

Production and development process

All steps from molecule design and synthesis of the effective residue and formulation of this radiopharmaceutical kit, cell studies and its pre-clinical work was done by internal specialists in Pars Isotope Company and the clinical phase of this radiopharmaceutical was successfully completed in 2 years with the cooperation of several universities of medical sciences in the country.

It should be noted that out of 50 types of radiopharmaceuticals produced, which are regularly and weekly sent to nuclear medicine centers, 35 of them are for Diagnosis of diseases or the function of organs (such as heart, kidney, liver, lung, brain, etc.), 19 types for the treatment of all types of cancer (thyroid, prostate, endocrine, etc.) and 6 types of palliative radiomedicine for pain are severe bone in cancers.

19 new radiopharmaceuticals in the clinical stage and preliminary trials

Also step by step Global developments in the field of radiopharmaceuticals and in line with the access of the people of our country to the latest diagnostic and therapeutic methods in the world, Pars Izotope company in the field of research and development of radiopharmaceuticals in cooperation with the Ministry of Health is implementing 8 new radiopharmaceutical projects.

These projects are in the clinical phase and good results have been obtained from them in the work of the new generation of alpha therapy in the treatment of breast cancer and prostate cancer, which after the successful completion of this phase, entered They will become the drug list of the country.

In this direction, eleven projects using the capacity of knowledge-based companies and the power of domestic experts are in the pre-clinical research phase and in the phase of animal studies and experiments. Is. Projects that will soon enter the human phase after being successful and obtaining permission from the ethics committees of medical science centers. The treatment produced in Iran, in addition to neighboring countries, countries from Asia, South America and Africa, are requesting these radiopharmaceuticals, and export to this country is on the agenda and follow-up.

end of message/